Sarcomas/TGCT | Specialty

Larotrectinib Elicits Durable Responses, Extends Survival in TRK+ Sarcomas

January 11th 2021

January 11, 2021 - Larotrectinib was found to induce a high response rate with long durability and improve survival in patients with TRK-positive sarcomas, according to results from an analysis of 3 clinical trials.

Dr. Dhir on Modifying Treatment for Adults Versus Pediatric Patients With Epithelioid Sarcoma

January 6th 2021

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

TP53, NF1 Among Genetic Variants Identified as Precursors to Pediatric Rhabdomyosarcoma

January 6th 2021

Germline predisposition variants associated with cancer susceptibility syndromes can underlie the genetic risk for rhabdomyosarcoma, indicating that germline testing should be performed in accordance with RMS subtypes and irrespective of age.

Dr. Trent on the Role of Adjuvant Imatinib in GIST

January 6th 2021

Jonathan C. Trent, MD, PhD, discusses the role of adjuvant imatinib in gastrointestinal stromal tumors.

Ripretinib Under Investigation for Second-Line GIST in Phase 3 INTRIGUE Trial

January 5th 2021

January 5th, 2021 - Ripretinib is under investigation as a second-line treatment in patients with gastrointestinal stromal tumor versus sunitinib in the phase 3 INTRIGUE trial, which recently completed its target enrollment.

Spotlighting Management Strategies Across Sarcoma Subtypes

January 4th 2021

Faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.

Phase 2/3 RINGSIDE Trial of AL102 Can Proceed in Desmoid Tumors

January 4th 2021

January 4, 2021 — The pivotal phase 2/3 RINGSIDE trial, which is evaluating the potent, selective oral gamma secretase inhibitor AL102, has been permitted to proceed and can potentially be used as a registrational study for adolescent and adult patients with desmoid tumors.

FDA Grants Annamycin Orphan Drug Status for Soft Tissue Sarcomas

December 29th 2020

December 29, 2020 - The FDA has granted an orphan drug designation to Annamycin for the treatment of patients with soft tissue sarcomas.

Entrectinib Continues to Elicit Durable Responses in NTRK Fusion–Positive Sarcoma

December 23rd 2020

December 23, 2020 - Entrectinib continued to demonstrate clinically meaningful, durable responses with a manageable toxicity profile in patients with NTRK fusion–positive sarcoma.

Up-Front Osteosarcoma Resection: An Approach Worth Exploring?

December 16th 2020

R. Lor Randall, MD, FACS, discusses the concept and prospect of up-front resection in osteosarcoma from the Osteosarcoma Collaborative.

x